Literature DB >> 8147342

Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease.

N Pancharuniti1, C A Lewis, H E Sauberlich, L L Perkins, R C Go, J O Alvarez, M Macaluso, R T Acton, R B Copeland, A L Cousins.   

Abstract

High plasma homocyst(e)ine (Hcy) concentrations may be a determinant of coronary artery disease (CAD). Folate and vitamin B-12 are required for the primary metabolic pathway to reduce Hcy concentrations. The interrelationships of Hcy and these two vitamin cofactors were investigated in a case-control study of 101 white males aged 30-50 y with angiographically demonstrated CAD, and 108 white male, similarly aged, control subjects living in the same community as the patients. The odds ratio (OR) of CAD per quartile increase of plasma Hcy concentration based on control values was 1.6 (95% CI: 1.3, 2.1). After age, HDL and LDL cholesterol, body mass index, smoking, hypertension, and diabetes were controlled for, Hcy remained an independent risk factor (OR: 1.4; 95% CI: 1.0, 2.0). The OR change per quartile increase of folate concentration was 0.8 (95% CI: 0.6, 1.0). This difference was reduced (OR: 0.9; 95% CI: 0.7, 1.2) after Hcy adjustment. No difference in the geometric mean of vitamin B-12 concentration was found between patients and control subjects, both 5.8 nmol/L. However, after Hcy and the other CAD risk factors were controlled for, the OR per quartile increase in vitamin B-12 concentration was 1.5 (95% CI: 1.0, 1.8). Reduction in plasma Hcy by interventions to increase plasma folate concentration may decrease CAD risk.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8147342     DOI: 10.1093/ajcn/59.4.940

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  31 in total

1.  The effect of a subnormal vitamin B-6 status on homocysteine metabolism.

Authors:  J B Ubbink; A van der Merwe; R Delport; R H Allen; S P Stabler; R Riezler; W J Vermaak
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

2.  Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in Type 2 diabetes mellitus.

Authors:  J Sun; Y Xu; Y Zhu; H Lu
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

3.  Effects of exercise training on pathological cardiac hypertrophy related gene expression and apoptosis.

Authors:  Young I Lee; Joon Y Cho; Mun H Kim; Kee B Kim; Dong J Lee; Kyu S Lee
Journal:  Eur J Appl Physiol       Date:  2006-04-01       Impact factor: 3.078

4.  Genes, greens, and homocysteine.

Authors:  R A Meleady; D A Mulcahy; I M Graham
Journal:  Heart       Date:  1996-08       Impact factor: 5.994

Review 5.  Role of folic acid in nitric oxide bioavailability and vascular endothelial function.

Authors:  Anna E Stanhewicz; W Larry Kenney
Journal:  Nutr Rev       Date:  2017-01       Impact factor: 7.110

6.  Effect of homocysteine thiolactone on structure and aggregation propensity of bovine pancreatic insulin.

Authors:  Shima Jalili; Reza Yousefi; Mohammad-Mehdi Papari; Ali Akbar Moosavi-Movahedi
Journal:  Protein J       Date:  2011-06       Impact factor: 2.371

7.  Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate.

Authors:  S L Tokgözoğlu; M Alikaşifoğlu; E Atalar; K Aytemir; N Ozer; K Ovünç; O Usal; S Kes; E Tunçbilek
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

Review 8.  The role of vitamins in the pathogenesis and treatment of hyperhomocyst(e)inaemia.

Authors:  J B Ubbink
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

9.  Serum total homocysteine and coronary heart disease: prospective study in middle aged men.

Authors:  P H Whincup; H Refsum; I J Perry; R Morris; M Walker; L Lennon; A Thomson; P M Ueland; S B Ebrahim
Journal:  Heart       Date:  1999-10       Impact factor: 5.994

10.  Anemia, serum vitamin B12, and folic acid in patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus.

Authors:  Refael Segal; Yehuda Baumoehl; Ori Elkayam; David Levartovsky; Irena Litinsky; Daphna Paran; Irena Wigler; Beni Habot; Arthur Leibovitz; Ben Ami Sela; Dan Caspi
Journal:  Rheumatol Int       Date:  2003-04-29       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.